ResearcherWayne State UniversityActive in the last 2 years
Eliza Wright Beal
Matched on ORCID iD 0000-0003-2191-6811; OpenAlex author ID A5079913663. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 8
- XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
- Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
- RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
- Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis Co-author DOI 10.1101/2023.12.18.572102↗
- Resection of a Pancreatic Ductal Adenocarcinoma With Pancreaticoduodenectomy in a Patient With a Prior Roux-en-Y Gastric Bypass and Retained Gastric Remnant. Last author DOI 10.1177/00031348231204903↗
- Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Co-author DOI 10.1007/s11605-022-05380-3↗
- Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10868-4↗
- Exosomes in Pancreatic Cancer: from Early Detection to Treatment. First author DOI 10.1007/s11605-018-3693-1↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sahar F. Bannoura · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Md. Hafiz Uddin · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Boris Pasche · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Husain Yar Khan · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Amro Aboukameel · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Asfar Sohail Azmi · 4 shared papers, 2023–2026 · strength 0.70
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Muhammad Wasif Saif · 3 shared papers, 2024–2026 · strength 0.54
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Ramzi M. Mohammad · 3 shared papers, 2024–2026 · strength 0.54
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Bassel F. El‐Rayes · 3 shared papers, 2024–2026 · strength 0.54
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Bin Bao · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
- Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
- Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
- Kay‐Uwe Wagner · 2 shared papers, 2023–2024 · strength 0.33
- Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
- Paper Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor… DOI 10.1101/2023.12.18.572102↗
- Morgan E. Jackson · 1 shared paper, 2023 · strength 0.26
- Timothy Michael Pawlik · 2 shared papers, 2018–2022 · strength 0.25
- Mary E. Dillhoff · 2 shared papers, 2018–2022 · strength 0.25
- Philip A. Philip · 1 shared paper, 2024 · strength 0.17
- Steve H. Kim · 1 shared paper, 2025 · strength 0.17
- Ahmad B. Hamad · 1 shared paper, 2022 · strength 0.16
- Mariam F. Eskander · 1 shared paper, 2022 · strength 0.16
- J. Madison Hyer · 1 shared paper, 2022 · strength 0.16
- Djhenne M. Dalmacy · 1 shared paper, 2022 · strength 0.16
- Alessandro Paro · 1 shared paper, 2022 · strength 0.16
- Allan Tsung · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.